These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11285791)

  • 21. [Intravesical Calmette-Guérin bacillus therapy of bladder tumors].
    Uchida T; Muruyama M; Igarashi M; Kobayashi K; Mashimo S; Ishibashi A; Koshiba K; Shibuya M
    Nihon Hinyokika Gakkai Zasshi; 1987 Dec; 78(12):2087-97. PubMed ID: 3451983
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
    Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
    Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of intravesical Bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder.
    Herr HW; Pinsky CM; Whitmore WF; Oettgen HF; Melamed MR
    Cancer; 1983 Apr; 51(7):1323-6. PubMed ID: 6337700
    [No Abstract]   [Full Text] [Related]  

  • 24. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 25. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
    Mulders PF; Meyden AP; Doesburg WH; Oosterhof GO; Debruyne FM
    Br J Urol; 1994 Apr; 73(4):403-8. PubMed ID: 8199828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimum management of non-muscle-invasive micropapillary variant urothelial carcinoma: possibility for missed chance of cure?
    Williams SB; Kamat AM
    BJU Int; 2016 Sep; 118(3):349-50. PubMed ID: 26917454
    [No Abstract]   [Full Text] [Related]  

  • 27. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
    Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ
    J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic and structural changes in the bladder after BCG intravesical therapy in men.
    Pagano F; Bassi P; Milani C; Dalla Palma P; Rebuffi AG; Poletti A; Parenti A
    Prog Clin Biol Res; 1989; 310():81-91. PubMed ID: 2771996
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunotherapy of bladder cancer.
    Nseyo UO; Lamm DL
    Semin Surg Oncol; 1997; 13(5):342-9. PubMed ID: 9259090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G
    Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [ImmuCyst intravesical (freeze-dried preparation made from the connaught strain of Bacillus Calmette Guérin) for the treatment of superficial bladder cancer and carcinoma in situ of urinary bladder].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):1027-38. PubMed ID: 12894724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
    Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
    Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
    Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
    J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer.
    Bassi P
    Surg Oncol; 2002 Jun; 11(1-2):77-83. PubMed ID: 12031870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCG treatment of superficial transitional cell carcinoma.
    Schellhammer PF
    Urology; 1991; 37(5 Suppl):16-8. PubMed ID: 2021030
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
    Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
    Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
    Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCG therapy of superficial bladder tumors.
    Herr HW
    Prog Clin Biol Res; 1989; 303():369-74. PubMed ID: 2674999
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.